A Phase 2/3 interventional study of Immune Globulin Intravenous (Human), 10% Solution and Immune Globulin Subcutaneous (Human), 20% Solution in Primary Immunodeficiency Diseases (PID), sponsored by Baxalta now part of Shire. Completed at 18 sites in 2 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2021-07-20.
Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases — 2 open to participants now, 4 under way, 4 of them phase 3. Immunoglobulins, Intravenous · Primary Immunodeficiency Diseases.
Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, this one is the 2nd largest by enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2013, is one of 3 in phase 2/3, and was the 9th registered.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
Browse Primary Immunodeficiency Diseases studies →2 of the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases are open now. Recruiting first, the newest first:
Azidus Brasil
Ages 2–60
Azidus Brasil
Ages 6–60
Immunoglobulins, Intravenous: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 21 · Phase 4 3
First in 2000; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 86 is above the median of 36 across 125 interventional studies indexed under Primary Immunodeficiency Diseases.
Median enrollment 45 across the 26 interventional studies. Of the 23 that completed or were terminated, 14 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 27 have an industry lead sponsor. The 10 most frequent:
This study is registered under Baxalta now part of Shire, one of the names counted as Takeda. Under that name alone:
Baxalta now part of Shire is the lead sponsor of 111 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
23 studies in Primary Immunodeficiency Diseases by Takeda: 2 open now, 3 under way, 1 of them phase 3. Of 19 finished, 12 (63%) have results posted.
Among the 23 studies in Primary Immunodeficiency Diseases by Takeda, this one is the 2nd largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2013, is one of 5 in phase 2/3, and was the 7th registered.
Takeda’s Primary Immunodeficiency Diseases studies by the year they started, since 2002.
2 of the studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04640142Phase 3OctapharmaStudy to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases | 2026-11 |
| NCT04944979Phase 3Kedrion S.p.A.Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, from their registry updates:
Among Takeda’s 23 in Primary Immunodeficiency Diseases:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to develop a 20% subcutaneous (SC) immunoglobulin preparation for the treatment of patients with primary immunodeficiency diseases (PIDD).
Main Inclusion Criteria:
Main Exclusion Criteria:
Abnormal laboratory values at screening meeting any one of the following criteria (abnormal tests may be repeated once to determine if they are persistent):
Women of meeting any one of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study. Epoch 2 (12-16 weeks): PK assessment (in first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated subcutaneously every 7 days at a dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1. Epoch 3 (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined. Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion.
Biological: Immune Globulin Intravenous (Human), 10% Solution · Drug: Immune Globulin Subcutaneous (Human), 20% Solution
Intravenous infusion with IGIV, 10%
Also known as: IGIV, 10%
Subcutaneous infusion with IGSC, 20%
Also known as: IGSC, 20%
Rate of Acute Serious Bacterial Infections Per Year (ASBI)
Annual rate of validated acute serious bacterial infections was calculated using a Poisson model to account for the different lengths of observation per participant. The observation period for each participant starts with the day of the first subcutaneous (SC) infusion in Study Epoch 2 and ends with the day of the End of Study visit.
Time frame: 1 year
Annual Rate of All Infections Per Participant
Time frame: 1 year
Annual Rate of Sinus Infections Per Participant
Time frame: 1 year
Annual Rate of Fever Episodes Per Participant
Time frame: 1 year
Annual Rate of Days Off School/Work or Days Unable to Perform Normal Daily Activities Due to Illness or Infection Per Participant
Time frame: 1 year
Annual Rate of Days on Antibiotics Per Participant
Time frame: 1 year
Annual Rate of Hospitalizations for Illness or Infection Per Participant
Time frame: 1 year
Annual Rate of Days of Hospitalizations for Illness or Infection Per Participant
Time frame: 1 year
Annual Rate of Acute (Urgent or Unscheduled) Physician Visits, or Visits to the Emergency Room for Illness or Infection Per Participant
Time frame: 1 year
Bioavailability of IGSC, 20% as Measured by the Ratio of the Geometric Means of Immunoglobulin G (IgG) AUCSC (Epoch 4) to IgG AUCIV,0-τ (Standardized to 1 Week) (Epoch 1) Adjusted for Dose and Dosing Frequency (Participants ≥12 Years Old)
IGSC, 20% = Immune Globulin Subcutaneous (Human), 20% Solution; AUCSC = area under the concentration-time curve following subcutaneous administration; AUCIV,0-τ = area under the concentration-time curve following intravenous administration over a dosing interval
Time frame: Epoch 1: 3 week IV administration interval: Week 10, 11, 12, 13. Epoch 1: 4 week IV interval: Week 9, 10, 11, 12, 13. Epoch 4 Subcutaneous administration weeks 17, 18
Trough Levels of IgG (Total), and IgG Subclasses at the End of the Treatment Intervals
Time frame: Epoch 1: 3 week IV interval- weeks 0, 1, 4, 7, 10, 13. Epoch 1: 4 week IV interval- weeks 0, 1, 5, 9, 13. Epochs 2 & 3: Subcutaneous (SC) weeks 5, 9. Epoch 4: SC weeks 1, 9, 17, 29, 40 (week dependent on time to establish "Adjusted Dose" in Epoch 2)
Trough Levels of Anti-Tetanus Antibody
Time frame: Epoch 1: 3 week IV interval- weeks 1, 4, 7, 10, 13. Epoch 1: 4 week IV interval- weeks 1, 5, 9, 13. Epochs 2 & 3: Subcutaneous (SC) weeks 5, 9. Epoch 4: SC weeks 1, 9, 17, 29, 40 (week dependent on time to establish "Adjusted Dose" in Epoch 2)
Trough Levels of Anti-Haemophilus Influenza B Antibody
Time frame: Epoch 1: 3 week IV interval- weeks 1, 4, 7, 10, 13. Epoch 1: 4 week IV interval- weeks 1, 5, 9, 13. Epochs 2 & 3: Subcutaneous (SC) weeks 5, 9. Epoch 4: SC weeks 1, 9, 17, 29, 40 (week dependent on time to establish "Adjusted Dose" in Epoch 2)
Trough Levels of Anti-Hepatitis B Antibody
Time frame: Epoch 1: 3 week IV interval- weeks 1, 4, 7, 10, 13. Epoch 1: 4 week IV interval- weeks 1, 5, 9, 13. Epochs 2 & 3: Subcutaneous (SC) weeks 5, 9. Epoch 4: SC weeks 1, 9, 17, 29, 40 (week dependent on time to establish "Adjusted Dose" in Epoch 2)
Pharmacokinetics Parameters for Immunoglobulin G (IgG): Area Under the Curve (AUC)
The AUC between adjacent infusions will be calculated by the trapezoidal rule. Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week)
Time frame: Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18
Pharmacokinetics Parameters for Immunoglobulin G (IgG): Dose Per Weight-adjusted Area Under the Curve (AUC)
The AUC between adjacent infusions will be calculated by the trapezoidal rule. Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week) adjusted for the dose per weight.
Time frame: Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18
Pharmacokinetics Parameters for Immunoglobulin G (IgG): Clearance (CL) for Immune Globulin Administered Intravenously (IGIV) and Apparent Clearance for Immune Globulin Administered Subcutaneously (IGSC)
Clearance (CL) or apparent clearance (CL/F) for IV and SC administration, respectively, will be determined by the formula: CL or CL/F = (Dose (mg/kg)) / (AUC 0-τ). (F= bioavailability)
Time frame: Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18
Pharmacokinetics Parameters for Immunoglobulin G (IgG): Maximum Concentration (Cmax)
The maximum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).
Time frame: Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18
Pharmacokinetics Parameters for Immunoglobulin G (IgG): Time to Maximum Concentration (Tmax)
The minimum time (Tmax) to reach the maximum concentration (Cmax)
Time frame: Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18
Pharmacokinetics Parameters for Immunoglobulin G (IgG): Minimum Concentration (Cmin)
The minimum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).
Time frame: Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18
Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Area Under the Curve (AUC)
The AUC between adjacent infusions will be calculated by the trapezoidal rule . Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC 0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week )
Time frame: Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18
Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Dose Per Weight-adjusted Area Under the Curve (AUC)
The AUC between adjacent infusions will be calculated by the trapezoidal rule . Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC 0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week) adjusted for the dose per weight.
Time frame: Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18
Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Clearance (CL) for Immune Globulin Administered Intravenously (IGIV) and Apparent Clearance (CL/F) for Immune Globulin Administered Subcutaneously
Clearance (CL) or apparent clearance (CL/F) for IV and SC administration, respectively, will be determined by the formula: CL or CL/F = (Dose (mg/kg)) / (AUC 0- τ). (F= bioavailability)
Time frame: Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18
Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Maximum Concentration (Cmax)
The maximum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).
Time frame: Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18
Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Time to Maximum Concentration (Tmax)
The minimum time (Tmax) to reach the maximum concentration (Cmax)
Time frame: Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18
Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Minimum Concentration (Cmin)
The minimum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).
Time frame: Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18
Correction Factor to Determine the Individually Adapted Dose in Study 170904 Epoch 4 (Dose Adjustment Table)
There is a high degree of variability in catabolism of immunoglobulin G (IgG) between individuals. To address this, trough levels immediately prior to the 9th weekly infusion in Epoch 3 were measured. The ratio of the measured trough levels on subcutaneous (SC) (Epoch 3) and intravenous (IV) administration (Epoch1) were compared to the expected trough level determined in Epoch 2. This was used to determine the Individually Adapted Dose to be used in Epoch 4. This was an interim study analysis.
Time frame: 29 weeks
Number of Serious (SAEs) and Non-serious Adverse Events (AEs) (Including and Excluding Infections) Deemed Related to the Investigational Product Per Participant
Number of related SAEs and AEs divided by number of participants
Time frame: Up to 20 months per subject (throughout entire study)
Number of Serious (SAEs) and Non-serious Adverse Events (AEs) (Including and Excluding Infections) Deemed Related to the Investigational Product Per Infusion
Number of related SAEs and AEs divided by number of subjects and divided by number of infusions
Time frame: Up to 20 months per subject (throughout entire study)
Number of Serious (SAEs) and Non-serious Adverse Events (AEs) (Including and Excluding Infections) Regardless of Relationship to the Investigational Product Per Participant
Number of all SAEs and AEs divided by number of participants
Time frame: Up to 20 months per subject (throughout entire study)
Number of Serious (SAEs) and Non-serious Adverse Events (AEs) (Including and Excluding Infections) Regardless of Relationship to the Investigational Product Per Infusion
Number of all SAEs and AEs divided by number of infusions
Time frame: Up to 20 months per subject (throughout entire study)
Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 72 Hours of Completion of Infusion Per Participant
Number of AEs that begin during or within 72 hours of completion of infusion divided by number of participants
Time frame: Within 72 hours of completion of infusion
Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 72 Hours of Completion of Infusion Per Infusion
Number of AEs that begin during or within 72 hours of completion of infusion divided by the number of infusions
Time frame: Within 72 hours of completion of infusion
Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 24 Hours of Completion of Infusion Per Participant
Number of AEs that begin during or within 24 hours of completion of infusion divided by number of participants
Time frame: Within 24 hours of completion of infusion
Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 24 Hours of Completion of Infusion Per Infusion
Number of AEs that begin during or within 24 hours of completion of infusion divided by number of infusions
Time frame: Within 24 hours of completion of infusion
Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 1 Hour of Completion of Infusion Per Participant
Number of AEs that begin during or within 1 hour of completion of infusion divided by number of participants
Time frame: Within 1 hour of completion of infusion
Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 1 Hour of Completion of Infusion
Number of AEs that begin during or within 1 hour of completion of infusion divided by number of infusions
Time frame: Within 1 hour of completion of infusion
Causally Related and/or Temporally Associated Adverse Events (AEs) Per Infusion
The total number of all AEs (including and excluding infections) that begin during infusion or within 72 hours of completion of an infusion ("temporally associated") plus the total number of AEs (including and excluding infections) starting more than 72 hours following the completion of an infusion determined by the investigator to be at least possibly related to the study drug("related"), divided by the total number of infusions
Time frame: Within 72 hours post infusion for Temporally Associated AEs; End of each Study Epoch (Epoch 1, Epoch 2, Epoch 3, and Epoch 4) for Causally Related AEs
Percentage of Infusions Associated With One or More Local Non-serious Adverse Events (Non-SAEs)
The number of infusions associated with local non-SAEs divided by the total number of infusions.
Time frame: Up to 20 months (throughout entire study)
Percentage of Participants Reporting One or More Local Non-serious Adverse Events (Non-SAEs)
Time frame: Up to 20 months (throughout entire study)
Number of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped Due to Tolerability Concerns or AEs
Time frame: Up to 20 months (throughout entire study)
Percentage of Participants for Whom the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped Due to Tolerability Concerns or AEs
Time frame: Up to 20 months (throughout entire study)
Percentage of Infusions Tolerated With Intravenous or Subcutaneous Administration
An infusion will be deemed as tolerated unless one of the following occurs: 1. Any serious related AE(s) 2. Any non-serious local or systemic related AE(s) that prevent(s) completion of infusion 3. Any severe non-serious local or systemic related AE(s) that occur within 60 minutes of completion of the infusion
Time frame: Up to 20 months (throughout entire study)
Short Term Tolerance - Change in Systolic Blood Pressure: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 1
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Systolic Blood Pressure: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 2
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Systolic Blood Pressure: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 3
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Systolic Blood Pressure: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 1
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Systolic Blood Pressure: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 2
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Systolic Blood Pressure: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 3
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Diastolic Blood Pressure: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 1
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Diastolic Blood Pressure: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 2
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Diastolic Blood Pressure: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 3
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Diastolic Blood Pressure: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 1
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Diastolic Blood Pressure: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 2
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Diastolic Blood Pressure: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 3
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Heart Rate (Pulse): Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 1
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Heart Rate (Pulse): Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 2
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Heart Rate (Pulse): Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 3
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Heart Rate (Pulse): Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 1
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Heart Rate (Pulse): Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 2
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Heart Rate (Pulse): Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 3
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Respiratory Rate: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 1
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Respiratory Rate: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 2
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Respiratory Rate: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 3
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Respiratory Rate: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 1
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Respiratory Rate: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 2
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Respiratory Rate: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 3
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Body Temperature: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 1
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Body Temperature: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 2
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Body Temperature: Immune Globulin Administered Intravenously (Human), 10% (IV 10%), Infusion 3
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Body Temperature: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 1
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Body Temperature: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 2
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Short Term Tolerance - Change in Body Temperature: Immune Globulin Administered Subcutaneously (Human), 20% (SC 20%), Infusion 3
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
Time frame: Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion
Number of Participants With Laboratory Confirmed Hemolysis That Occurred Following Investigational Product Administration
Laboratory tests for confirmation of potential hemolysis include Coomb's test, haptoglobin, free hemoglobin, reticulocyte count, lactate dehydrogenase (LDH), and urine hemosiderin.
Time frame: Epoch 1: 3 week IV interval- weeks 0, 10. Epoch 1: 4 week IV interval- weeks 0, 9. Epoch 3: Subcutaneous (SC) week 9. Epoch 4: SC weeks 17, 18, 40
Quality of Life- Pediatric Quality of Life Inventory^TM (PEDS-QL^TM) (Observer: Parent) for the Age Group 2 to 7 Years
The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. Higher scores indicate better quality of life (QoL) for all domains of the Peds-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, \& school functioning) are scored. 2 summary scores (Psychosocial Health Summary, and Physical Health Summary) are presented, along with a total score.
Time frame: Up to 20 months (throughout entire study)
Quality of Life- PEDS-QL^TM (Observer: Participant) for the Age Group 8 to 13 Years of Age
The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. Higher scores indicate better quality of life (QoL) for all domains of the Peds-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, \& school functioning) are scored. 2 summary scores (Psychosocial Health Summary, and Physical Health Summary) are presented, along with a total score.
Time frame: Up to 20 months (throughout entire study)
Quality of Life- Short-Form 36v2 (SF-36v2) for the Age Group 14 Years and Older
The PCS is a summary scale of the dimensions physical functioning, role physical, bodily pain, and general health. The component score is normalized to a standard population. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both sub-scores and summary scores.
Time frame: Up to 20 months (throughout entire study)
Treatment Satisfaction Questionnaire for Medication (TSQM) - 2 to 12 Years Old
TSQM; for the age group 2 to 12 years the observer will be a parent. Treatment Satisfaction Questionnaire for Medication (TSQM) is a global satisfaction scale used to assess the overall level of participant's satisfaction or dissatisfaction with their medications. The following 3 domain were included: effectiveness, convenience, and global satisfaction. The score of each of the 3 domains is based on an algorithm to create a score of 0 to 100. Higher score indicated greater satisfaction in that domain.
Time frame: Up to 20 months per subject (throughout entire study)
Treatment Satisfaction Questionnaire for Medication (TSQM) - 13 Years and Older
TSQM; for the age group 13 years and older the observer will be the participant. Treatment Satisfaction Questionnaire for Medication (TSQM) is a global satisfaction scale used to assess the overall level of participant's satisfaction or dissatisfaction with their medications. The following 3 domain were included: effectiveness, convenience, and global satisfaction. The score of each of the 3 domains is based on an algorithm to create a score of 0 to 100. Higher score indicated greater satisfaction in that domain.
Time frame: Up to 20 months per subject (throughout entire study)
Life Quality Index - 2 to 12 Years Old
For the age group 2 to 12 years the respondent will be a parent. Each of the four domains has a separate score, each has a different range as follows: Treatment Interference Score Range: 6-42, Therapy-related Problems Score Range: 4-28, Therapy Setting Score Range: 3-21, Cost Score Range: 2-14. Higher scores represent more satisfaction with various aspects of treatment.
Time frame: Up to 20 months (throughout entire study)
Life Quality Index - 13 Years and Older
For the age group 13 years and older the respondent will be the participant. Each of the four domains has a separate score, each has a different range as follows: Treatment Interference Score Range: 6-42, Therapy-related Problems Score Range: 4-28, Therapy Setting Score Range: 3-21, Cost Score Range: 2-14. Higher scores represent more satisfaction with various aspects of treatment.
Time frame: Up to 20 months per subject (throughout entire study)
Participants were enrolled (signed informed consent) at 15 sites.
| Milestone | Study Participants |
|---|---|
| Started | 77 |
| Completed | 74 |
| Not completed | 3 |
| Withdrew: Physician decision | 2 |
| Withdrew: Adverse event | 1 |
| Milestone | Study Participants |
|---|---|
| Started | 45 |
| Completed | 45 |
| Not completed | 0 |
| Milestone | Study Participants |
|---|---|
| Started | 74 |
| Completed | 70 |
| Not completed | 4 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Adverse event | 1 |
| Milestone | Study Participants |
|---|---|
| Started | 70 |
| Completed | 67 |
| Not completed | 3 |
| Withdrew: Physician decision | 1 |
| Withdrew: Withdrawal by subject | 2 |
Annual rate of validated acute serious bacterial infections was calculated using a Poisson model to account for the different lengths of observation per participant. The observation period for each participant starts with the day of the first subcutaneous (SC) infusion in Study Epoch 2 and ends with the day of the End of Study visit.
| Estimated infections/ year | Study Participants |
|---|---|
| Rate of Acute Serious Bacterial Infections Per Year (ASBI) | 0.012 |
| Estimated infections/year | Intravenous 10% - Epoch 1 | Subcutaneous 20% - Epochs 2 Thru 4 |
|---|---|---|
| Annual Rate of All Infections Per Participant | 3.86 (2.77 to 5.22) | 2.41 (1.89 to 3.03) |
| Estimated infections/year | Intravenous 10% - Epoch 1 | Subcutaneous 20% - Epochs 2 Thru 4 |
|---|---|---|
| Annual Rate of Sinus Infections Per Participant | 0.97 (0.61 to 1.45) | 0.69 (0.50 to 0.93) |
| Estimated episodes/year | Intravenous 10% - Epoch 1 | Subcutaneous 20% - Epochs 2 Thru 4 |
|---|---|---|
| Annual Rate of Fever Episodes Per Participant | 0.61 (0.34 to 0.99) | 0.13 (0.08 to 0.21) |
| Estimated days off/participant | Intravenous 10% - Epoch 1 | Subcutaneous 20% - Epochs 2 Thru 4 |
|---|---|---|
| Annual Rate of Days Off School/Work or Days Unable to Perform Normal Daily Activities Due to Illness or Infection Per Participant | 3.20 (1.88 to 5.03) | 1.16 (0.70 to 1.79) |
| Estimated days/particpant | Intravenous 10% - Epoch 1 | Subcutaneous 20% - Epochs 2 Thru 4 |
|---|---|---|
| Annual Rate of Days on Antibiotics Per Participant | 63.20 (43.39 to 88.29) | 57.59 (40.71 to 78.59) |
| Estimated hospitalizations/participant | Intravenous 10% - Epoch 1 | Subcutaneous 20% - Epochs 2 Thru 4 |
|---|---|---|
| Annual Rate of Hospitalizations for Illness or Infection Per Participant | 0.05 (0.02 to 0.10) | 0.02 (0.01 to 0.04) |
| Estimated days/participant | Intravenous 10% - Epoch 1 | Subcutaneous 20% - Epochs 2 Thru 4 |
|---|---|---|
| Annual Rate of Days of Hospitalizations for Illness or Infection Per Participant | 0.20 (0.08 to 0.42) | 0.11 (0.05 to 0.20) |
| Estimated visits/participant | Intravenous 10% - Epoch 1 | Subcutaneous 20% - Epochs 2 Thru 4 |
|---|---|---|
| Annual Rate of Acute (Urgent or Unscheduled) Physician Visits, or Visits to the Emergency Room for Illness or Infection Per Participant | 1.73 (1.03 to 2.68) | 0.86 (0.54 to 1.28) |
IGSC, 20% = Immune Globulin Subcutaneous (Human), 20% Solution; AUCSC = area under the concentration-time curve following subcutaneous administration; AUCIV,0-τ = area under the concentration-time curve following intravenous administration over a dosing interval
| Ratio | Study Epochs 1-4 |
|---|---|
| Bioavailability of IGSC, 20% as Measured by the Ratio of the Geometric Means of Immunoglobulin G (IgG) AUCSC (Epoch 4) to IgG AUCIV,0-τ (Standardized to 1 Week) (Epoch 1) Adjusted for Dose and Dosing Frequency (Participants ≥12 Years Old) | 1.0855 (1.0394 to 1.1336) |
| g/L | IV 10% 3 Weeks | IV 10% 4 Weeks | SC 20% 145% IV 1 Week | SC 20% Adjusted 1 Week | SC 20% Individualized 1 Week |
|---|---|---|---|---|---|
| Total IgG | 11.58 (10.36 to 12.94) | 10.19 (9.55 to 10.88) | 14.77 (13.86 to 15.74) | 14.20 (13.48 to 14.96) | 14.74 (14.03 to 15.48) |
| IgG Subclass 1 | 6.23 (5.47 to 7.09) | 5.45 (5.04 to 5.91) | 8.06 (7.51 to 8.65) | 7.83 (7.33 to 8.38) | 7.41 (6.98 to 7.87) |
| IgG Subclass 2 | 3.92 (3.53 to 4.35) | 3.30 (3.08 to 3.54) | 4.83 (4.47 to 5.21) | 4.95 (4.65 to 5.26) | 4.94 (4.69 to 5.20) |
| IgG Subclass 3 | 0.352 (0.285 to 0.435) | 0.405 (0.347 to 0.473) | 0.516 (0.463 to 0.574) | 0.514 (0.458 to 0.578) | 0.514 (0.456 to 0.580) |
| IgG Subclass 4 | 0.239 (0.202 to 0.281) | 0.186 (0.165 to 0.209) | 0.309 (0.273 to 0.350) | 0.304 (0.280 to 0.331) | 0.311 (0.289 to 0.335) |
| IU/mL | Overall Study Arm |
|---|---|
| Pre-Study Medication- Epoch 1 Week 1 (N= 64) | 2.28 (1.84 to 2.82) |
| IV 10% 3 Weeks- Epoch 1 Week 4 (N= 15) | 3.36 (2.44 to 4.63) |
| IV 10% 3 Weeks- Epoch 1 Week 7 (N= 16) | 2.66 (2.04 to 3.48) |
| IV 10% 3 Weeks - Epoch 1 Week 10 (N= 19) | 2.55 (1.83 to 3.56) |
| IV 10% 3 Weeks- Epoch 1 Week 13 (N= 16) | 2.26 (1.52 to 3.37) |
| IV 10% 4 Weeks- Epoch 1 Week 5 (N= 46) | 1.92 (1.44 to 2.56) |
| IV 10% 4 Weeks- Epoch 1 Week 9 (N= 44) | 2.31 (1.79 to 2.96) |
| IV 10% 4 Weeks- Epoch 1 Week 13 (N= 43) | 2.28 (1.84 to 2.81) |
| SC 20% 145% IV 1 Week- Epoch 2 Week 5 (N= 29) | 4.08 (3.12 to 5.33) |
| SC 20% 145% IV 1 Week- Epoch 2 Week 9 (N= 27) | 4.49 (3.32 to 6.08) |
| SC 20% adjusted 1 Week- Epoch 3 Week 5 (N= 55) | 3.76 (3.21 to 4.40) |
| SC 20% adjusted 1 Week- Epoch 3 Week 9 (N= 58) | 3.09 (2.64 to 3.62) |
| SC 20% adjusted 1 Week- Epoch 4 Week 1 (N= 62) | 2.75 (2.39 to 3.17) |
| SC 20% individualized 1 Week Epoch 4 Week 9 (N=58) | 3.15 (2.73 to 3.63) |
| SC 20% individualized 1 Week Epoch 4 Week 17(N=51) | 3.17 (2.74 to 3.67) |
| SC 20% individualized 1 Week Epoch 4 Week 29(N=54) | 1.74 (1.48 to 2.03) |
| SC 20% individualized 1 Week- End of Study (N= 53) | 1.97 (1.66 to 2.32) |
| mg/L | Overall Study Arm |
|---|---|
| Pre-Study Medication- Epoch 1 Week 1 (N= 65) | 2.91 (2.55 to 3.34) |
| IV 10% 3 Weeks- Epoch 1 Week 4 (N= 15) | 2.71 (2.07 to 3.56) |
| IV 10% 3 Weeks- Epoch 1 Week 7 (N= 16) | 3.08 (2.36 to 4.01) |
| IV 10% 3 Weeks- Epoch 1 Week 10 (N= 19) | 2.42 (1.75 to 3.36) |
| IV 10% 3 Weeks- Epoch 1 Week 13 (N= 14) | 2.47 (1.85 to 3.29) |
| IV 10% 4 Weeks- Epoch 1 Week 5 (N= 45) | 2.82 (2.30 to 3.46) |
| IV 10% 4 Weeks- Epoch 1 Week 9 (N= 44) | 2.71 (2.23 to 3.30) |
| IV 10% 4 Weeks- Epoch 1 Week 13 (N= 43) | 2.74 (2.20 to 3.42) |
| SC 20% 145% IV 1 Week- Epoch 2 Week 5 (N= 29) | 4.07 (3.44 to 4.83) |
| SC 20% 145% IV 1 Week- Epoch 2 Week 9 (N= 27) | 3.94 (3.30 to 4.71) |
| SC 20% adjusted 1 Week- Epoch 3 Week 5 (N= 56) | 3.59 (3.12 to 4.14) |
| SC 20% adjusted 1 Week- Epoch 3 Week 9 (N= 58) | 3.62 (3.10 to 4.22) |
| SC 20% adjusted 1 Week- Epoch 4 Week 1 (N= 62) | 3.47 (3.06 to 3.94) |
| SC 20% individualized 1 Week Epoch 4 Week 9 (N=58) | 4.35 (3.87 to 4.89) |
| SC 20% individualized 1 Week Epoch 4 Week 17(N=51) | 4.76 (4.21 to 5.39) |
| SC 20% individualized 1 Week Epoch 4 Week 29(N=54) | 4.06 (3.55 to 4.65) |
| SC 20% individualized 1 Week- End of Study (N= 52) | 5.07 (4.48 to 5.73) |
| mIU/mL | Study Epochs 1-4 |
|---|---|
| Pre-Study Medication- Epoch 1 Week 1 (N= 66) | 266.6 (232.3 to 305.9) |
| IV 10% 3 Weeks- Epoch 1 Week 4 (N= 15) | 357.8 (312.2 to 410.1) |
| IV 10% 3 Weeks- Epoch 1 Week 7 (N= 17) | 402.6 (333.4 to 486.0) |
| IV 10% 3 Weeks- Epoch 1 Week 10 (N= 19) | 376.6 (315.7 to 449.3) |
| IV 10% 3 Weeks- Epoch 1 Week 13 (N= 16) | 392.2 (310.4 to 495.6) |
| IV 10% 4 Weeks- Epoch 1 Week 5 (N= 45) | 301.1 (266.2 to 340.5) |
| IV 10% 4 Weeks- Epoch 1 Week 9 (N= 44) | 304.0 (271.0 to 341.0) |
| IV 10% 4 Weeks- Epoch 1 Week 13 (N= 43) | 296.3 (266.0 to 330.2) |
| SC 20% 145% IV 1 Week- Epoch 2 Week 5 (N= 29) | 463.7 (425.0 to 506.0) |
| SC 20% 145% IV 1 Week- Epoch 2 Week 9 (N= 27) | 525.0 (478.1 to 576.5) |
| SC 20% adjusted 1 Week- Epoch 3 Week 5 (N= 57) | 581.9 (533.4 to 634.9) |
| SC 20% adjusted 1 Week- Epoch 3 Week 9 (N= 58) | 622.4 (579.8 to 668.1) |
| SC 20% adjusted 1 Week- Epoch 4 Week 1 (N= 62) | 552.8 (509.7 to 599.6) |
| SC 20% individualized 1 Week Epoch 4 Week 9(N= 58) | 434.4 (400.4 to 471.2) |
| SC 20% individualized 1 Week Epoch 4 Week 17(N=53) | 444.5 (408.2 to 484.1) |
| SC 20% individualized 1 Week Epoch 4 Week 29(N=54) | 389.2 (355.9 to 425.7) |
| SC 20% individualized 1 Week- End of Study (N=56) | 403.1 (371.7 to 437.1) |
The AUC between adjacent infusions will be calculated by the trapezoidal rule. Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week)
| g*days/L | Study Epoch 1: IGIV 10% Every 3 Weeks | Study Epoch 1: IGIV 10% Every 4 Weeks | Study Epoch 2: IGSC 20 %, 145 % of IGIV 10 % | Study Epoch 4: IGSC 20 %, Individualized Dose |
|---|---|---|---|---|
| Pharmacokinetics Parameters for Immunoglobulin G (IgG): Area Under the Curve (AUC) | 352.05 (319.74 to 387.63) | 410.40 (381.24 to 441.79) | 108.33 (97.60 to 120.24) | 115.21 (109.23 to 121.52) |
The AUC between adjacent infusions will be calculated by the trapezoidal rule. Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week) adjusted for the dose per weight.
| (g*days/L)/(g/kg) | Study Epoch 1: IGIV 10% Every 3 Weeks | Study Epoch 1: IGIV 10% Every 4 Weeks | Study Epoch 2: IGSC 20 %, 145 % of IGIV 10 % | Study Epoch 4: IGSC 20 %, Individualized Dose |
|---|---|---|---|---|
| Pharmacokinetics Parameters for Immunoglobulin G (IgG): Dose Per Weight-adjusted Area Under the Curve (AUC) | 606.99 (495.29 to 743.87) | 796.30 (715.36 to 886.40) | 472.50 (411.07 to 543.10) | 536.05 (495.58 to 579.82) |
Clearance (CL) or apparent clearance (CL/F) for IV and SC administration, respectively, will be determined by the formula: CL or CL/F = (Dose (mg/kg)) / (AUC 0-τ). (F= bioavailability)
| mL/kg/days | Study Epoch 1: IGIV 10% Every 3 Weeks | Study Epoch 1: IGIV 10% Every 4 Weeks | Study Epoch 2: IGSC 20 %, 145 % of IGIV 10 % | Study Epoch 4: IGSC 20 %, Individualized Dose |
|---|---|---|---|---|
| Pharmacokinetics Parameters for Immunoglobulin G (IgG): Clearance (CL) for Immune Globulin Administered Intravenously (IGIV) and Apparent Clearance for Immune Globulin Administered Subcutaneously (IGSC) | 1.65 (1.34 to 2.02) | 1.26 (1.13 to 1.40) | 2.12 (1.84 to 2.43) | 1.87 (1.72 to 2.02) |
The maximum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).
| g/L | Study Epoch 1: IGIV 10% Every 3 Weeks | Study Epoch 1: IGIV 10% Every 4 Week | Study Epoch 2: IGSC 20 %, 145 % of IGIV 10 % | Study Epoch 4: IGSC 20 %, Individualized Dose |
|---|---|---|---|---|
| Pharmacokinetics Parameters for Immunoglobulin G (IgG): Maximum Concentration (Cmax) | 27.09 (24.30 to 30.19) | 24.85 (23.18 to 26.64) | 17.31 (15.11 to 19.82) | 19.31 (18.13 to 20.57) |
The minimum time (Tmax) to reach the maximum concentration (Cmax)
| hours (h) | Study Epoch 1: IGIV 10% Every 3 Weeks | Study Epoch 1: IGIV 10% Every 4 Weeks | Study Epoch 2: IGSC 20 %, 145 % of IGIV 10 % | Study Epoch 4: IGSC 20 %, Individualized Dose |
|---|---|---|---|---|
| Pharmacokinetics Parameters for Immunoglobulin G (IgG): Time to Maximum Concentration (Tmax) | 6.94 (3.96 to 12.17) | 5.84 (3.62 to 9.40) | 54.19 (36.28 to 80.92) | 78.68 (65.37 to 94.70) |
The minimum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).
| g/L | Study Epoch 1: IGIV 10% Every 3 Weeks | Study Epoch 1: IGIV 10% Every 4 Weeks | Study Epoch 2: IGSC 20 %, 145 % of IGIV 10 % | Study Epoch 4: IGSC 20 %, Individualized Dose |
|---|---|---|---|---|
| Pharmacokinetics Parameters for Immunoglobulin G (IgG): Minimum Concentration (Cmin) | 12.03 (10.64 to 13.60) | 10.37 (9.50 to 11.33) | 13.85 (12.61 to 15.21) | 14.00 (13.14 to 14.91) |
The AUC between adjacent infusions will be calculated by the trapezoidal rule . Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC 0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week )
| mg*days/L | Study Epoch 1: IGIV 10% Every 3 Weeks | Study Epoch 1: IGIV 10% Every 4 Weeks | Study Epoch 2: IGSC 20 %, 145 % of IGIV 10 % | Study Epoch 4: IGSC 20 %, Individualized Dose |
|---|---|---|---|---|
| Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Area Under the Curve (AUC) | 80.79 (65.58 to 99.53) | 123.05 (93.36 to 162.18) | 29.51 (23.25 to 37.46) | 30.64 (26.29 to 35.72) |
The AUC between adjacent infusions will be calculated by the trapezoidal rule . Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC 0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week) adjusted for the dose per weight.
| (mg*days/L)/(g/kg) | Study Epoch 1: IGIV 10% Every 3 Weeks | Study Epoch 1: IGIV 10% Every 4 Weeks | Study Epoch 2: IGSC 20 %, 145 % of IGIV 10 % | Study Epoch 4: IGSC 20 %, Individualized Dose |
|---|---|---|---|---|
| Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Dose Per Weight-adjusted Area Under the Curve (AUC) | 139.29 (110.89 to 174.97) | 239.99 (181.92 to 316.61) | 128.72 (96.65 to 171.42) | 141.78 (121.75 to 165.12) |
Clearance (CL) or apparent clearance (CL/F) for IV and SC administration, respectively, will be determined by the formula: CL or CL/F = (Dose (mg/kg)) / (AUC 0- τ). (F= bioavailability)
| mL/kg/days | Study Epoch 1: IGIV 10% Every 3 WeeksOverall Study Arm | Study Epoch 1: IGIV 10% Every 4 Weeks | Study Epoch 2: IGSC 20%, 145% of IGIV 10% | Study Epoch 4: IGSC 20%, Individualized Dose |
|---|---|---|---|---|
| Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Clearance (CL) for Immune Globulin Administered Intravenously (IGIV) and Apparent Clearance (CL/F) for Immune Globulin Administered Subcutaneously | 7.18 (5.72 to 9.02) | 4.17 (3.16 to 5.50) | 7.77 (5.83 to 10.35) | 7.05 (6.06 to 8.21) |
The maximum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).
| mg/L | Study Epoch 1: IGIV 10% Every 3 Weeks | Study Epoch 1: IGIV 10% Every 4 Weeks | Study Epoch 2: IGSC 20%, 145% of IGIV 10% | Study Epoch 4: IGSC 20 %, Individualized Dose |
|---|---|---|---|---|
| Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Maximum Concentration (Cmax) | 6.31 (5.25 to 7.59) | 7.22 (5.75 to 9.05) | 4.40 (3.45 to 5.62) | 4.86 (4.16 to 5.68) |
The minimum time (Tmax) to reach the maximum concentration (Cmax)
| Hours (s) | Study Epoch 1: IGIV 10% Every 3 Weeks | Study Epoch 1: IGIV 10% Every 4 Weeks | Study Epoch 2: IGSC 20 %, 145 % of IGIV 10 % | Study Epoch 4: IGSC 20 %, Individualized Dose |
|---|---|---|---|---|
| Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Time to Maximum Concentration (Tmax) | 3.11 (2.69 to 3.59) | 3.71 (2.69 to 5.12) | 70.67 (51.14 to 97.66) | 66.87 (56.22 to 79.53) |
The minimum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).
| mg/L | Study Epoch 1: IGIV 10% Every 3 Weeks | Study Epoch 1: IGIV 10% Every 4 Weeks | Study Epoch 2: IGSC 20%, 145% of IGIV 10% | Study Epoch 4: IGSC 20%, Individualized Dose |
|---|---|---|---|---|
| Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Minimum Concentration (Cmin) | 2.82 (2.20 to 3.61) | 3.13 (2.31 to 4.26) | 3.97 (3.14 to 5.01) | 3.71 (3.15 to 4.37) |
There is a high degree of variability in catabolism of immunoglobulin G (IgG) between individuals. To address this, trough levels immediately prior to the 9th weekly infusion in Epoch 3 were measured. The ratio of the measured trough levels on subcutaneous (SC) (Epoch 3) and intravenous (IV) administration (Epoch1) were compared to the expected trough level determined in Epoch 2. This was used to determine the Individually Adapted Dose to be used in Epoch 4. This was an interim study analysis.
| Correction factor | Correction Factor |
|---|---|
| Trough Level Ratio: 0.93 or more | 1.16 |
| Trough Level Ratio: 0.94 | 1.14 |
| Trough Level Ratio: 0.95 to 0.96 | 1.12 |
| Trough Level Ratio: 0.97 to 0.98 | 1.11 |
| Trough Level Ratio: 0.99 to 1.01 | 1.10 |
| Trough Level Ratio: 1.02 to 1.04 | 1.09 |
| Trough Level Ratio: 1.05 to 1.08 | 1.08 |
| Trough Level Ratio: 1.09 to 1.13 | 1.07 |
| Trough Level Ratio: 1.14 to 1.19 | 1.06 |
| Trough Level Ratio: 1.20 to 1.26 | 1.05 |
| Trough Level Ratio: 1.27 to 1.33 | 1.04 |
| Trough Level Ratio: 1.34 to 1.40 | 1.03 |
| Trough Level Ratio: 1.41 to 1.47 | 1.02 |
| Trough Level Ratio: 1.48 to 1.55 | 1.01 |
| Trough Level Ratio: 1.56 to 1.63 | 1.00 |
Number of related SAEs and AEs divided by number of participants
| Adverse events per participant | INTRAVENOUS 10% | SUBCUTANEOUS 20% |
|---|---|---|
| Non-SAEs - Including infections | 1.039 | 2.122 |
| Non-SAEs - Excluding infections | 1.039 | 2.122 |
| SAEs - Including infections | 0.013 | 0 |
| SAEs - Excluding infections | 0.013 | 0 |
Number of related SAEs and AEs divided by number of subjects and divided by number of infusions
| Adverse events per infusion | INTRAVENOUS 10% | SUBCUTANEOUS 20% |
|---|---|---|
| Non-SAEs - Including Infections | 0.247 | 0.036 |
| Non-SAEs -Excluding Infections | 0.247 | 0.036 |
| SAEs - Including Infections | 0.003 | 0 |
| SAEs -Excluding Infections | 0.003 | 0 |
Number of all SAEs and AEs divided by number of participants
| Adverse events per participant | INTRAVENOUS 10% | SUBCUTANEOUS 20% |
|---|---|---|
| Non-SAEs - Including infections | 3.325 | 9.014 |
| Non-SAEs - Excluding infections | 2.338 | 6.297 |
| SAEs - Including infections | 0.013 | 0.027 |
| SAEs - Excluding infections | 0.013 | 0.014 |
Number of all SAEs and AEs divided by number of infusions
| Adverse events per infusion | IGIV, 10% | Subcutaneous, 20% |
|---|---|---|
| Non-SAEs - Including infections | 0.390 | 0.114 |
| Non-SAEs - Excluding infections | 0.296 | 0.079 |
| SAEs - including infections | 0.003 | 0.000 |
| SAEs - Excluding infections | 0.003 | 0.000 |
Number of AEs that begin during or within 72 hours of completion of infusion divided by number of participants
| Adverse events per participant | Intravenous 10% | Subcutaneous 20% |
|---|---|---|
| Non-SAEs - Including infections | 1.377 | 4.581 |
| Non-SAEs - Excluding infections | 1.260 | 3.703 |
| SAEs - Including infections | 0.013 | 0 |
| SAEs - Excluding infections | 0.013 | 0 |
Number of AEs that begin during or within 72 hours of completion of infusion divided by the number of infusions
| Adverse events per infusion | Intravenous 10% | Subcutaneous 20% |
|---|---|---|
| Non-SAEs - Including infections | 0.327 | 0.078 |
| Non-SAEs - Excluding infections | 0.299 | 0.063 |
| SAEs - Including infections | 0.003 | 0 |
| SAEs - Excluding infections | 0.003 | 0 |
Number of AEs that begin during or within 24 hours of completion of infusion divided by number of participants
| Adverse events per participant | Intravenous 10% | Subcutaneous 20% |
|---|---|---|
| Non-SAEs - Including infections | 0.961 | 3.365 |
| Non-SAEs - Excluding infections | 0.948 | 3.027 |
| SAEs - Including infections | 0 | 0 |
| SAEs - Excluding infections | 0 | 0 |
Number of AEs that begin during or within 24 hours of completion of infusion divided by number of infusions
| Adverse events per infusion | Intravenous 10% | Subcutaneous 20% |
|---|---|---|
| Non-SAEs - Including infections | 0.228 | 0.058 |
| Non-SAEs - Excluding infections | 0.225 | 0.052 |
| SAEs - Including infections | 0 | 0 |
| SAEs - Excluding infections | 0 | 0 |
Number of AEs that begin during or within 1 hour of completion of infusion divided by number of participants
| Adverse events per participant | Intravenous 10% | Subcutaneous 20% |
|---|---|---|
| Non-SAEs - Including infections | 0.662 | 1.865 |
| Non-SAEs - Excluding infections | 0.662 | 1.797 |
| SAEs - Including infections | 0 | 0 |
| SAEs - Excluding infections | 0 | 0 |
Number of AEs that begin during or within 1 hour of completion of infusion divided by number of infusions
| Adverse events per infusion | Intravenous 10% | Subcutaneous 20% |
|---|---|---|
| Non-SAEs - Including infections | 0.157 | 0.032 |
| Non-SAEs - Excluding infections | 0.157 | 0.031 |
| SAEs - Including infections | 0 | 0 |
| SAEs - Excluding infections | 0 | 0 |
The total number of all AEs (including and excluding infections) that begin during infusion or within 72 hours of completion of an infusion ("temporally associated") plus the total number of AEs (including and excluding infections) starting more than 72 hours following the completion of an infusion determined by the investigator to be at least possibly related to the study drug("related"), divided by the total number of infusions
| Adverse events per infusion | Intravenous 10% | Subcutaneous 20% |
|---|---|---|
| Non-SAEs - Including infections | 0.336 | 0.079 |
| Non-SAEs - Excluding infections | 0.309 | 0.064 |
| SAEs - Including infections | 0.003 | 0 |
| SAEs - Excluding infections | 0.003 | 0 |
The number of infusions associated with local non-SAEs divided by the total number of infusions.
| Percent of infusions | Intravenous 10% | Subcutaneous 20% |
|---|---|---|
| Percentage of Infusions Associated With One or More Local Non-serious Adverse Events (Non-SAEs) | 0.9 | 1.8 |
| Percent of participants | Intravenous 10% | Subcutaneous 20% |
|---|---|---|
| Percentage of Participants Reporting One or More Local Non-serious Adverse Events (Non-SAEs) | 3.9 | 31.1 |
| Infusions | Intravenous 10% | Subcutaneous 20% |
|---|---|---|
| Infusion rate reduced | 4 | 5 |
| Infusion interrupted | 5 | 2 |
| Infusion stopped | 0 | 1 |
| Percent of participants | Intravenous 10% | Subcutaneous 20% |
|---|---|---|
| Infusion rate reduced | 1.3 | 5.4 |
| Infusion interrupted | 6.5 | 1.4 |
| Infusion stopped | 0.0 | 1.4 |
An infusion will be deemed as tolerated unless one of the following occurs: 1. Any serious related AE(s) 2. Any non-serious local or systemic related AE(s) that prevent(s) completion of infusion 3. Any severe non-serious local or systemic related AE(s) that occur within 60 minutes of completion of the infusion
| Percent of infusions | Intravenous 10% | Subcutaneous 20% |
|---|---|---|
| Percentage of Infusions Tolerated With Intravenous or Subcutaneous Administration | 100 | 100 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 61 | 1 | 1 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 10 | 1 | 1 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 1 | 0 | 1 | 0 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 62 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 5 | 2 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 1 | 0 | 1 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 2 | 0 | 1 | 0 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 59 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 9 | 2 | 2 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 1 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 0 | 0 | 1 | 0 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 38 | 1 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 1 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 2 | 1 | 1 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 0 | 1 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 35 | 2 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 2 | 1 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 0 | 0 | 0 | 1 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 32 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 2 | 1 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 0 | 0 | 0 | 1 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 69 | 0 | 1 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 2 | 0 | 2 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 0 | 1 | 0 | 1 | 0 |
| Maximum Post-Infusion Grade 3 | 1 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 67 | 0 | 1 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 3 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 1 | 2 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 69 | 1 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 1 | 2 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 1 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 41 | 1 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 0 | 1 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 1 | 1 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 37 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 2 | 1 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 0 | 0 | 1 | 0 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 35 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 0 | 0 | 1 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 61 | 3 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 8 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 2 | 1 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 0 | 0 | 1 | 1 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 53 | 3 | 1 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 9 | 2 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 4 | 0 | 1 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 0 | 1 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 55 | 1 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 9 | 2 | 1 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 2 | 2 | 2 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 40 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 1 | 2 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 2 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 36 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 2 | 2 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 1 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 32 | 2 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 1 | 1 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 32 | 5 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 7 | 28 | 1 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 0 | 2 | 2 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 35 | 2 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 11 | 19 | 1 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 0 | 1 | 2 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 0 | 1 | 0 | 2 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 32 | 4 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 6 | 26 | 2 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 0 | 2 | 0 | 1 | 0 |
| Maximum Post-Infusion Grade 3 | 0 | 0 | 0 | 1 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 18 | 1 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 9 | 17 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 18 | 1 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 4 | 18 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 13 | 6 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 5 | 11 | 1 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 77 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 73 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 1 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered intravenously (Human), 10% (IV 10%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 72 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 2 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 45 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 41 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Vital signs measured pre-infusion, during infusion, and post-infusion of Immune globulin administered subcutaneously (Human), 20% (SC 20%) was graded by the investigator and the sponsor using a 4-grade scale: mild (grade 1), moderate (grade 2), severe (grade 3) or life-threatening (grade 4) according to the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September2007. \*Note 5th Grade (grade 0) added to scale to reflect within normal range.
| Participants | Pre-Infusion Toxicity Grade 0 | Pre-Infusion Toxicity Grade 1 | Pre-Infusion Toxicity Grade 2 | Pre-Infusion Toxicity Grade 3 | Pre-Infusion Toxicity Grade 4 |
|---|---|---|---|---|---|
| Maximum Post-Infusion Grade 0 | 36 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 1 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 2 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Maximum Post-Infusion Grade 4 | 0 | 0 | 0 | 0 | 0 |
Laboratory tests for confirmation of potential hemolysis include Coomb's test, haptoglobin, free hemoglobin, reticulocyte count, lactate dehydrogenase (LDH), and urine hemosiderin.
| Participants | Intravenous 10% | Subcutaneous 20% |
|---|---|---|
| Number of Participants With Laboratory Confirmed Hemolysis That Occurred Following Investigational Product Administration | 0 | 0 |
The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. Higher scores indicate better quality of life (QoL) for all domains of the Peds-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, \& school functioning) are scored. 2 summary scores (Psychosocial Health Summary, and Physical Health Summary) are presented, along with a total score.
| Score on a scale | Start of Study Epoch 1 | End of Study Epoch 1 | End of Study Epoch 3 | End of Study Epoch 4 | Change End Epoch 1 to End Epoch 3 | Change End Epoch 1 to End Epoch 4 |
|---|---|---|---|---|---|---|
| Physical Functioning | 95.31 (68.75 to 100.00) | 93.75 (56.25 to 100.00) | 96.88 (62.50 to 100.00) | 92.19 (75.00 to 100.00) | 1.56 (-3.13 to 9.38) | 1.56 (-12.50 to 18.75) |
| Emotional Functioning | 95.00 (70.00 to 95.00) | 85.00 (50.00 to 95.00) | 82.50 (60.00 to 100.00) | 77.50 (55.00 to 85.00) | 0.00 (-5.00 to 10.00) | -2.50 (-20.00 to 10.00) |
| Social Functioning | 95.00 (65.00 to 100.00) | 95.00 (25.00 to 100.00) | 97.50 (25.00 to 100.00) | 87.50 (50.00 to 100.00) | 0.00 (-5.00 to 10.00) | 0.00 (-15.00 to 25.00) |
| School Functioning | 85.00 (55.00 to 100.00) | 75.00 (30.00 to 83.33) | 81.67 (40.00 to 100.00) | 67.50 (25.00 to 91.67) | 7.50 (0.00 to 25.00) | -5.00 (-10.00 to 8.33) |
| Psychosocial Health Summary | 91.67 (65.00 to 98.08) | 83.33 (38.33 to 92.31) | 84.17 (41.67 to 100.00) | 77.50 (46.67 to 90.38) | 2.50 (0.00 to 11.67) | -3.33 (-8.33 to 8.33) |
| Physical Health Summary | 95.31 (68.75 to 100.00) | 93.75 (56.25 to 100.00) | 96.88 (62.50 to 100.00) | 92.19 (75.00 to 100.00) | 1.56 (-3.13 to 9.38) | 1.56 (-12.50 to 18.75) |
| Total Score | 92.93 (69.57 to 98.81) | 86.96 (59.78 to 94.05) | 88.04 (60.87 to 100.00) | 82.61 (60.87 to 94.05) | 1.63 (0.00 to 10.87) | 0.00 (-5.43 to 4.35) |
The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. Higher scores indicate better quality of life (QoL) for all domains of the Peds-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, \& school functioning) are scored. 2 summary scores (Psychosocial Health Summary, and Physical Health Summary) are presented, along with a total score.
| Score on a scale | Start of Epoch 1 | End of Epoch 1 | End of Epoch 3 | End of Epoch 4 | Change End of Epoch 1 to End of Epoch 3 | Change End of Epoch 1 to End of Epoch 4 |
|---|---|---|---|---|---|---|
| Physical Functioning | 89.06 (81.25 to 100.00) | 90.63 (78.13 to 100.00) | 87.50 (75.00 to 100.00) | 93.75 (71.88 to 100.00) | 0.00 (-3.13 to 9.38) | 6.25 (0.00 to 15.63) |
| Emotional Functioning | 87.50 (75.00 to 100.00) | 80.00 (70.00 to 90.00) | 80.00 (70.00 to 95.00) | 87.50 (65.00 to 95.00) | 0.00 (-5.00 to 5.00) | 10.00 (-5.00 to 15.00) |
| Social Functioning | 87.50 (80.00 to 100.00) | 95.00 (80.00 to 100.00) | 95.00 (85.00 to 100.00) | 95.00 (85.00 to 100.00) | 0.00 (0.00 to 5.00) | 0.00 (0.00 to 5.00) |
| School Functioning | 75.00 (55.00 to 90.00) | 80.00 (60.00 to 85.00) | 75.00 (55.00 to 85.00) | 70.00 (55.00 to 85.00) | 0.00 (-10.00 to 10.00) | -2.50 (-15.00 to 10.00) |
| Psychosocial Health Summary | 80.83 (76.67 to 91.67) | 83.33 (71.67 to 91.67) | 81.67 (75.00 to 93.33) | 81.67 (78.33 to 91.67) | 0.00 (-3.33 to 8.33) | 3.33 (-1.67 to 10.00) |
| Physical Health Summary | 89.06 (81.25 to 100.00) | 90.63 (78.13 to 100.00) | 87.50 (75.00 to 100.00) | 93.75 (71.88 to 100.00) | 0.00 (-3.13 to 9.38) | 6.25 (0.00 to 15.63) |
| Total Score | 86.41 (82.61 to 94.57) | 89.13 (69.57 to 91.30) | 81.52 (76.09 to 93.48) | 85.87 (79.35 to 92.39) | 1.09 (-1.09 to 7.61) | 2.17 (-3.26 to 10.87) |
The PCS is a summary scale of the dimensions physical functioning, role physical, bodily pain, and general health. The component score is normalized to a standard population. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both sub-scores and summary scores.
| Scores on a scale | START OF STUDY EPOCH 1 | END OF STUDY EPOCH 1 | END OF STUDY EPOCH 3 | END OF STUDY EPOCH 4 | CHANGE END EPOCH 1 TO END EPOCH 3 | CHANGE END EPOCH 1 TO END EPOCH 4 |
|---|---|---|---|---|---|---|
| Physical Functioning | 48.61 (46.51 to 52.82) | 52.82 (44.41 to 54.93) | 50.72 (48.61 to 52.82) | 50.72 (46.51 to 54.93) | 0.00 (-2.10 to 0.00) | 0.00 (-2.10 to 2.10) |
| Role-Physical | 44.61 (37.26 to 49.51) | 42.16 (37.26 to 51.96) | 49.51 (42.16 to 54.40) | 47.06 (44.61 to 51.96) | 2.45 (0.00 to 4.90) | 2.45 (0.00 to 4.90) |
| Bodily Pain | 43.95 (41.41 to 51.13) | 45.64 (37.18 to 50.29) | 50.29 (41.83 to 51.13) | 46.06 (41.83 to 51.13) | 4.23 (0.00 to 4.65) | 0.00 (0.00 to 4.65) |
| General Health | 38.63 (33.87 to 41.02) | 41.02 (33.87 to 44.83) | 38.63 (36.25 to 45.78) | 38.63 (36.25 to 45.78) | 0.95 (-1.43 to 2.38) | 0.72 (-2.38 to 2.38) |
| Vitality | 42.72 (39.60 to 48.97) | 42.72 (36.48 to 48.97) | 45.85 (39.60 to 52.09) | 48.97 (42.72 to 52.09) | 3.12 (0.00 to 3.12) | 1.56 (0.00 to 6.24) |
| Social Functioning | 45.94 (40.49 to 51.40) | 45.94 (40.49 to 51.40) | 51.40 (45.94 to 51.40) | 51.40 (45.94 to 56.85) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 5.45) |
| Role-Emotional | 51.99 (44.22 to 55.88) | 55.88 (48.10 to 55.88) | 51.99 (48.10 to 55.88) | 53.94 (44.22 to 55.88) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
| Mental Health | 50.01 (47.19 to 52.82) | 52.82 (47.19 to 55.64) | 50.01 (47.19 to 52.82) | 52.82 (50.01 to 55.64) | 0.00 (-2.82 to 2.82) | 1.41 (-2.82 to 2.82) |
| Physical Component Summary | 41.57 (38.01 to 47.02) | 39.93 (37.57 to 47.98) | 46.13 (43.00 to 50.84) | 46.07 (42.38 to 49.25) | 1.22 (-0.51 to 3.29) | 0.89 (-0.37 to 2.49) |
| Mental Component Summary | 49.92 (45.53 to 51.78) | 49.45 (46.87 to 53.58) | 49.70 (46.37 to 54.06) | 51.59 (48.03 to 54.35) | 0.57 (-2.17 to 2.39) | 1.31 (-3.69 to 4.40) |
TSQM; for the age group 2 to 12 years the observer will be a parent. Treatment Satisfaction Questionnaire for Medication (TSQM) is a global satisfaction scale used to assess the overall level of participant's satisfaction or dissatisfaction with their medications. The following 3 domain were included: effectiveness, convenience, and global satisfaction. The score of each of the 3 domains is based on an algorithm to create a score of 0 to 100. Higher score indicated greater satisfaction in that domain.
| Score on a scale | Start of Epoch 1 | End of Epoch 1 | End of Epoch 3 | End of Epoch 4 | Change End of Epoch 1 to End of Epoch 3 | Change End of Epoch 1 to End of Epoch 4 |
|---|---|---|---|---|---|---|
| Effectiveness | 83.33 (77.78 to 100.00) | 88.89 (83.33 to 100.00) | 83.33 (66.67 to 100.00) | 91.67 (72.22 to 100.00) | 0.00 (-11.11 to 0.00) | 0.00 (-5.56 to 5.56) |
| Convenience | 75.00 (55.56 to 88.89) | 72.22 (66.67 to 83.33) | 80.56 (77.78 to 100.00) | 77.78 (77.78 to 94.44) | 5.56 (0.00 to 27.78) | 5.56 (0.00 to 16.67) |
| Global Satisfaction | 85.71 (78.57 to 100.00) | 92.86 (71.43 to 100.00) | 100.00 (71.43 to 100.00) | 89.29 (71.43 to 100.00) | 0.00 (0.00 to 7.14) | 0.00 (0.00 to 7.14) |
TSQM; for the age group 13 years and older the observer will be the participant. Treatment Satisfaction Questionnaire for Medication (TSQM) is a global satisfaction scale used to assess the overall level of participant's satisfaction or dissatisfaction with their medications. The following 3 domain were included: effectiveness, convenience, and global satisfaction. The score of each of the 3 domains is based on an algorithm to create a score of 0 to 100. Higher score indicated greater satisfaction in that domain.
| Score on a scale | Start of Epoch 1 | End of Epoch 1 | End of Epoch 3 | End of Epoch 4 | Change End of Epoch 1 to End of Epoch 3 | Change End of Epoch 1 to End of Epoch 4 |
|---|---|---|---|---|---|---|
| Effectiveness | 77.78 (72.22 to 83.33) | 80.56 (72.22 to 88.89) | 83.33 (77.78 to 88.89) | 83.33 (77.78 to 88.89) | 0.00 (0.00 to 5.56) | 0.00 (0.00 to 5.56) |
| Convenience | 66.67 (61.11 to 77.78) | 66.67 (55.56 to 72.22) | 83.33 (72.22 to 83.33) | 83.33 (77.78 to 88.89) | 11.11 (5.56 to 16.67) | 11.11 (5.56 to 16.67) |
| Global Satisfaction | 85.71 (78.57 to 92.86) | 85.71 (78.57 to 92.86) | 92.86 (78.57 to 92.86) | 92.86 (85.71 to 92.86) | 0.00 (0.00 to 7.14) | 0.00 (0.00 to 7.14) |
For the age group 2 to 12 years the respondent will be a parent. Each of the four domains has a separate score, each has a different range as follows: Treatment Interference Score Range: 6-42, Therapy-related Problems Score Range: 4-28, Therapy Setting Score Range: 3-21, Cost Score Range: 2-14. Higher scores represent more satisfaction with various aspects of treatment.
| Score on a scale | Start of Epoch 1 | End of Epoch 1 | End of Epoch 3 | End of Epoch 4 | Change End of Epoch 1 to End of Epoch 3 | Change End of Epoch 1 to End of Epoch 4 |
|---|---|---|---|---|---|---|
| Treatment Interference | 32.0 (27.0 to 40.0) | 31.0 (30.0 to 41.0) | 35.0 (31.0 to 39.0) | 34.5 (30.0 to 39.0) | 0.0 (-2.0 to 5.0) | -0.5 (-2.0 to 9.0) |
| Therapy-related Problems | 23.0 (20.0 to 24.0) | 23.0 (22.0 to 26.0) | 22.0 (20.0 to 24.0) | 21.5 (21.0 to 25.0) | 0.0 (-2.0 to 0.0) | -1.0 (-3.0 to 0.0) |
| Therapy Settings | 18.0 (17.0 to 21.0) | 18.0 (16.0 to 20.0) | 19.0 (18.0 to 21.0) | 20.0 (17.0 to 21.0) | 0.0 (0.0 to 3.0) | 1.0 (-1.0 to 3.0) |
| Costs | 9.0 (8.0 to 11.0) | 11.0 (10.0 to 13.0) | 11.0 (11.0 to 12.0) | 10.5 (9.0 to 13.0) | 1.0 (0.0 to 2.0) | -0.5 (-1.0 to 2.0) |
For the age group 13 years and older the respondent will be the participant. Each of the four domains has a separate score, each has a different range as follows: Treatment Interference Score Range: 6-42, Therapy-related Problems Score Range: 4-28, Therapy Setting Score Range: 3-21, Cost Score Range: 2-14. Higher scores represent more satisfaction with various aspects of treatment.
| Score on a scale | Start of Epoch 1 | End of Epoch 1 | End of Epoch 3 | End of Epoch 4 | Change End of Epoch 1 to End of Epoch 3 | Change End of Epoch 1 to End of Epoch 4 |
|---|---|---|---|---|---|---|
| Treatment Interference | 34.0 (30.0 to 37.0) | 34.5 (32.0 to 36.0) | 37.0 (35.0 to 39.0) | 38.5 (34.0 to 40.0) | 1.0 (0.0 to 4.0) | 3.0 (0.0 to 5.0) |
| Therapy-related Problems | 23.0 (22.0 to 24.0) | 22.5 (21.0 to 24.0) | 24.0 (22.0 to 25.0) | 24.0 (23.0 to 25.0) | 0.0 (-1.0 to 2.0) | 1.0 (-1.0 to 2.0) |
| Therapy Settings | 18.0 (16.0 to 19.0) | 17.0 (16.0 to 18.0) | 20.0 (19.0 to 20.0) | 20.0 (19.0 to 21.0) | 1.0 (0.0 to 3.0) | 2.0 (0.0 to 3.0) |
| Costs | 8.0 (7.0 to 10.0) | 10.0 (9.0 to 10.0) | 11.5 (10.0 to 13.0) | 13.0 (11.0 to 14.0) | 1.0 (0.0 to 2.0) | 1.5 (1.0 to 3.0) |
Collected over Throughout the 4 Study Epochs. Epoch 1: 13 weeks. Epoch 2: 12-16 weeks Epoch 3: 12 weeks Epoch 4: 40 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Study Epoch 1: Intravenous 10% Treatment | — | 1/77 (1.3%) | 46/77 (59.7%) |
| Study Epochs 2-4: Subcutaneous 20% Treatment | — | 2/74 (2.7%) | 59/74 (79.7%) |
| Event | Study Epoch 1: Intravenous 10% Treatment | Study Epochs 2-4: Subcutaneous 20% Treatment |
|---|---|---|
| PneumoniaInfections and infestations | 0/77 | 1/74 |
| Lung adenocarcinimaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/77 | 1/74 |
| HeadacheNervous system disorders | 1/77 | 0/74 |
| Event | Study Epoch 1: Intravenous 10% Treatment | Study Epochs 2-4: Subcutaneous 20% Treatment |
|---|---|---|
| HeadacheNervous system disorders | 23/77 | 12/74 |
| SinusitisInfections and infestations | 7/77 | 18/74 |
| Acute sinusitisInfections and infestations | 6/77 | 15/74 |
| Upper respiratory tract infectionInfections and infestations | 8/77 | 14/74 |
| Infusion site painGeneral disorders | 0/77 | 14/74 |
| NauseaGastrointestinal disorders | 6/77 | 11/74 |
| BronchitisNervous system disorders | 3/77 | 11/74 |
| DiarrhoeaGastrointestinal disorders | 4/77 | 8/74 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/77 | 8/74 |
| Infusion site erythemaGeneral disorders | 0/77 | 8/74 |
Safety Analysis Dataset: All participants who received at least one dose of immunoglobulin.
| Age, Continuous(Years) | Study Epochs 1-4 |
|---|---|
| Median | 36.0 (3 to 83) |
| Sex: Female, Male(Participants) | Study Epochs 1-4 |
|---|---|
| Female | 37 |
| Male | 40 |
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jan 2013 to primary completion in Mar 2015, 25 months.
Results were first posted in Feb 2017, 1 year 11 months after primary completion. A results delay was requested in May 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Immunoglobulins, Intravenous · Homo sapiens whole
Primary Immunodeficiency Diseases →